Furthermore, evaluation of the antitumour effects of combined therapy with canine AD-MSCs producing IFN-β and cisplatin in B16F10 melanoma-bearing mice revealed that intratumoural administration of cisplatin combined with subcutaneous injection of engineered AD-MSCs exhibited superior effects compared to the administration of modified AD-MSCs or cisplatin alone in terms of melanoma tumour development inhibition and survival rate (63). The gene discussed is IFNB1; the disease is melanoma.